Management of ductal carcinoma in situ

Hetelekidis, Stella; Schnitt, Stuart J.; Morrow, Monica; Harris, Jay R.

doi:10.3322/canjclin.45.4.244

Cited by 21 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For patients who have DCIS or stage I invasive carcinoma, the risk for a regional nodal recurrence is 0% to 5%, 51,63,[74][75][76] and only the breast is treated (most commonly, two portals whose central axes are aimed tangential to the chest wall). For stage II invasive carcinoma, whether after conservative surgery or mastectomy, each patient's risk for regional nodal recurrence is evaluated individually.…”

Section: Is the Volume To Be Treated Always The Same?mentioning

confidence: 99%

Radiotherapy for In Situ, Stage I, and Stage II Breast Cancer

Stevens¹

2005

Breast Cancer

View full text Add to dashboard Cite

Section: Is the Volume To Be Treated Always The Same?mentioning

confidence: 99%

Radiotherapy for In Situ, Stage I, and Stage II Breast Cancer

Stevens¹

2005

Breast Cancer

View full text Add to dashboard Cite

“…The *Address correspondence to this author at the Department of Radiology 1 Silverstein Building University of Pennsylvania Health System 3400 Spruce Street Philadelphia, PA 19104, USA; Tel: 215-662-6726; Fax: 215-614-0124; E-mail: susan.weinstein@uphs.upenn.edu calcifications seen on mammography represent necrotic cells [4]. This results as the cells outgrow their blood supply leading to hypoxia and cell death.…”

Section: Introductionmentioning

confidence: 99%

Imaging Intraductal Carcinoma

Weinstein¹

2012

CCTR

View full text Add to dashboard Cite

Intraductal carcinoma (DCIS) was once an uncommon disease. Today, DCIS represents 20-30% of breast cancers that are diagnosed. Mammography has been the gold standard in detecting DCIS, however recent evidence demonstrates that magnetic resonance imaging (MRI) may be superior to mammography in detecting DCIS. In addition, MRI may be able to detect high grade, mammographically occult DCIS that are more likely to progress on to become invasive carcinoma.

show abstract

“…[11][12][13] Ductal carcinoma in situ ͑DCIS͒ is not only the most commonly diagnosed early-stage cancer in the breast but also the most commonly targeted lesion in breast biopsy procedures. 12,[14][15][16] Of 100 DCIS cases investigated by Stomper et al using breast mammography, 22% of the lesions were smaller than 5 mm and 75% of the lesions were smaller than 20 mm. 17 For successful sampling of these lesions, the needle must be accurately placed at the target.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic mammography imaging combined with 3D US imaging for image guided breast biopsy

et al. 2007

View full text Add to dashboard Cite

Stereotactic X-ray mammography (SM) and ultrasound (US) guidance are both commonly used for breast biopsy. While SM provides three-dimensional (3D) targeting information and US provides real-time guidance, both have limitations. SM is a long and uncomfortable procedure and the US guided procedure is inherently two dimensional (2D), requiring a skilled physician for both safety and accuracy. The authors developed a 3D US-guided biopsy system to be integrated with, and to supplement SM imaging. Their goal is to be able to biopsy a larger percentage of suspicious masses using US, by clarifying ambiguous structures with SM imaging. Features from SM and US guided biopsy were combined, including breast stabilization, a confined needle trajectory, and dual modality imaging. The 3D US guided biopsy system uses a 7.5 MHz breast probe and is mounted on an upright SM machine for preprocedural imaging. Intraprocedural targeting and guidance was achieved with real-time 2D and near real-time 3D US imaging. Postbiopsy 3D US imaging allowed for confirmation that the needle was penetrating the target. The authors evaluated 3D US-guided biopsy accuracy of their system using test phantoms. To use mammographic imaging information, they registered the SM and 3D US coordinate systems. The 3D positions of targets identified in the SM images were determined with a target localization error (TLE) of 0.49 mm. The z component (x-ray tube to image) of the TLE dominated with a TLEz of 0.47 mm. The SM system was then registered to 3D US, with a fiducial registration error (FRE) and target registration error (TRE) of 0.82 and 0.92 mm, respectively. Analysis of the FRE and TRE components showed that these errors were dominated by inaccuracies in the z component with a FREz of 0.76 mm and a TREz of 0.85 mm. A stereotactic mammography and 3D US guided breast biopsy system should include breast compression for stability and safety and dual modality imaging for target localization. The system will provide preprocedural x-ray mammography information in the form of SM imaging along with real-time US imaging for needle guidance to a target. 3D US imaging will also be available for targeting, guidance, and biopsy verification immediately postbiopsy.

show abstract

Management of ductal carcinoma in situ

Cited by 21 publications

References 34 publications

Radiotherapy for In Situ, Stage I, and Stage II Breast Cancer

Radiotherapy for In Situ, Stage I, and Stage II Breast Cancer

Imaging Intraductal Carcinoma

Stereotactic mammography imaging combined with 3D US imaging for image guided breast biopsy

Contact Info

Product

Resources

About